- Home
- Publications
- Publication Search
- Publication Details
Title
EGFR/HER-targeted therapeutics in ovarian cancer
Authors
Keywords
-
Journal
Future Medicinal Chemistry
Volume 4, Issue 4, Pages 447-469
Publisher
Future Science, LTD
Online
2012-03-15
DOI
10.4155/fmc.12.11
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Searching for a system: The quest for ovarian cancer biomarkers
- (2017) Karin D. Rodland et al. Cancer Biomarkers
- Phase I/II lapatinib plus carboplatin and paclitaxel in stage III or IV relapsed ovarian cancer patients
- (2017) S. E. Rivkin et al. JOURNAL OF CLINICAL ONCOLOGY
- The Role of Cytoreductive/Debulking Surgery in Ovarian Cancer
- (2017) Mark T. Wakabayashi et al. Journal of the National Comprehensive Cancer Network
- Cancer statistics, 2012
- (2012) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
- (2011) A. Goldhirsch et al. ANNALS OF ONCOLOGY
- Identification of Immunoreactive Regions of Homology between Soluble Epidermal Growth Factor Receptor and α5-Integrin
- (2011) Jason A. Wilken et al. BIOCHEMISTRY
- p95HER2 and Breast Cancer
- (2011) J. Arribas et al. CANCER RESEARCH
- Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma
- (2011) S. John Weroha et al. GYNECOLOGIC ONCOLOGY
- A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: A gynecologic oncology group study
- (2011) Agustin A. Garcia et al. GYNECOLOGIC ONCOLOGY
- Big Costs for Little Gain in Ovarian Cancer
- (2011) Martee L. Hensley JOURNAL OF CLINICAL ONCOLOGY
- MEK1/2 Inhibitor Selumetinib (AZD6244) Inhibits Growth of Ovarian Clear Cell Carcinoma in a PEA-15-Dependent Manner in a Mouse Xenograft Model
- (2011) C. Bartholomeusz et al. MOLECULAR CANCER THERAPEUTICS
- Modeling high-grade serous ovarian carcinogenesis from the fallopian tube
- (2011) A. M. Karst et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The PI3 kinase/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells
- (2010) Caroline Brünner-Kubath et al. BREAST CANCER RESEARCH AND TREATMENT
- The epidermal growth factor receptor conundrum
- (2010) Jason A. Wilken et al. CANCER
- HER Kinase Axis Receptor Dimer Partner Switching Occurs in Response to EGFR Tyrosine Kinase Inhibition despite Failure to Block Cellular Proliferation
- (2010) A. Jain et al. CANCER RESEARCH
- Vandetanib, Designed to Inhibit VEGFR2 and EGFR Signaling, Had No Clinical Activity as Monotherapy for Recurrent Ovarian Cancer and No Detectable Modulation of VEGFR2
- (2010) C. M. Annunziata et al. CLINICAL CANCER RESEARCH
- Phase II study of gefitinib in combination with paclitaxel (P) and carboplatin (C) as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma (1839IL/0074)
- (2010) Patricia Pautier et al. GYNECOLOGIC ONCOLOGY
- A phase II study of erlotinib (OSI-774) given in combination with carboplatin in patients with recurrent epithelial ovarian cancer (NCIC CTG IND.149)
- (2010) H. Hirte et al. GYNECOLOGIC ONCOLOGY
- Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: A phase II study based on surgical reassessment
- (2010) Stephanie V. Blank et al. GYNECOLOGIC ONCOLOGY
- Phosphatidic Acid Induces Ligand-independent Epidermal Growth Factor Receptor Endocytic Traffic through PDE4 Activation
- (2010) Andrés Norambuena et al. MOLECULAR BIOLOGY OF THE CELL
- Bevacizumab plus Low-Dose Metronomic Oral Cyclophosphamide in Heavily Pretreated Patients with Recurrent Ovarian Cancer
- (2010) Alfonso Sánchez-Muñoz et al. ONCOLOGY
- Trastuzumab Sensitizes Ovarian Cancer Cells to EGFR-targeted Therapeutics
- (2010) Jason A Wilken et al. Journal of Ovarian Research
- Trichostatin A sensitizes human ovarian cancer cells to TRAIL-induced apoptosis by down-regulation of c-FLIPL via inhibition of EGFR pathway
- (2009) Soo-Jung Park et al. BIOCHEMICAL PHARMACOLOGY
- HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy
- (2009) Jessica N McAlpine et al. BMC CANCER
- Trastuzumab-Induced HER Reprogramming in "Resistant" Breast Carcinoma Cells
- (2009) M. Narayan et al. CANCER RESEARCH
- Crosstalk Between Epidermal Growth Factor Receptor- and Insulin-Like Growth Factor-1 Receptor Signaling: Implications for Cancer Therapy
- (2009) J. Veeken et al. CURRENT CANCER DRUG TARGETS
- Update on Hsp90 Inhibitors in Clinical Trial
- (2009) Y. Kim et al. CURRENT TOPICS IN MEDICINAL CHEMISTRY
- Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash
- (2009) Russell J. Schilder et al. GYNECOLOGIC ONCOLOGY
- Clinical Activity of Gemcitabine Plus Pertuzumab in Platinum-Resistant Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
- (2009) Sharmila Makhija et al. JOURNAL OF CLINICAL ONCOLOGY
- Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor–Targeted Therapy in Metastatic Colorectal Cancer
- (2009) Salvatore Siena et al. JNCI-Journal of the National Cancer Institute
- A Naturally Occurring HER2 Carboxy-Terminal Fragment Promotes Mammary Tumor Growth and Metastasis
- (2009) K. Pedersen et al. MOLECULAR AND CELLULAR BIOLOGY
- Ovarian cancer: front-line standard treatment in 2008
- (2008) P. A. Vasey ANNALS OF ONCOLOGY
- Epidermal growth factor receptor gene copy number, K-ras mutation and pathological response to preoperative cetuximab, 5-FU and radiation therapy in locally advanced rectal cancer
- (2008) C. Bengala et al. ANNALS OF ONCOLOGY
- The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer
- (2008) P de Graeff et al. BRITISH JOURNAL OF CANCER
- A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers
- (2008) P A Vasey et al. BRITISH JOURNAL OF CANCER
- Matuzumab Binding to EGFR Prevents the Conformational Rearrangement Required for Dimerization
- (2008) Judith Schmiedel et al. CANCER CELL
- Curcumin attenuates EGF-induced AQP3 up-regulation and cell migration in human ovarian cancer cells
- (2008) Chao Ji et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Priming with EGFR tyrosine kinase inhibitor and EGF sensitizes ovarian cancer cells to respond to chemotherapeutical drugs
- (2008) Cong Cao et al. CANCER LETTERS
- Mutant Epidermal Growth Factor Receptor in Benign, Borderline, and Malignant Ovarian Tumors
- (2008) K. D. Steffensen et al. CLINICAL CANCER RESEARCH
- The biological properties of cetuximab
- (2008) Bruno Vincenzi et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Implications of EGFR inhibition in ovarian cancer cell proliferation
- (2008) Shawna L. Bull Phelps et al. GYNECOLOGIC ONCOLOGY
- Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: A trial of the Chicago, PMH, and California Phase II consortia
- (2008) Halla S. Nimeiri et al. GYNECOLOGIC ONCOLOGY
- A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer
- (2008) Jason Konner et al. GYNECOLOGIC ONCOLOGY
- Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: A Gynecologic Oncology Group study
- (2008) Angeles Alvarez Secord et al. GYNECOLOGIC ONCOLOGY
- A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations
- (2008) Ann K. Folkins et al. GYNECOLOGIC ONCOLOGY
- Chemoresistant tumor cell lines display altered epidermal growth factor receptor and HER3 signaling and enhanced sensitivity to gefitinib
- (2008) Tiziana Servidei et al. INTERNATIONAL JOURNAL OF CANCER
- Rab-coupling protein coordinates recycling of α5β1 integrin and EGFR1 to promote cell migration in 3D microenvironments
- (2008) Patrick T. Caswell et al. JOURNAL OF CELL BIOLOGY
- Reversal of Drug Resistance in Ovarian Cancer: Where Do We Go From Here?
- (2008) Stan B. Kaye JOURNAL OF CLINICAL ONCOLOGY
- HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924
- (2008) P. Haluska et al. MOLECULAR CANCER THERAPEUTICS
- HER2Status and Benefit from Adjuvant Trastuzumab in Breast Cancer
- (2008) Soonmyung Paik et al. NEW ENGLAND JOURNAL OF MEDICINE
- K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer
- (2008) Christos S. Karapetis et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now